IL6 and plasma cell myeloma: In a clinical trial (NCT00635154), the use of IL-1Ra treatment in combination with dexamethasone in patients suffering from mild precursor conditions with the risk of developing an active form of MM caused a reduction in myeloma growth and an improvement in PFS [90] as, in addition to the maximum inhibition of IL-6 synthesis, apoptosis of myeloma cells was also observed [90].